Women experiencing postpartum depression – estimated to affect one in seven new mothers – soon may be able to benefit from a non-pharmaceutical alternative for treatment: Curio Digital Therapeutics’ MamaLift Plus.
The US Food and Drug Administration granted Curio 510(k) clearance in April for MamaLift Plus, a first-of-its-kind, prescription-only digital therapeutic...







